التكنولوجيا وأخبارها بوابة الإمارات لتكنولوجيا المعلومات والإتصالات
New Data to Be Presented at the ISTH 2020 Virtual Congress Demonstrating Octapharma’s Commitment to Patients With Bleeding Disorders
Octapharma announced today that new research findings
from its haematology portfolio will be presented at the
upcoming International Society on Thrombosis and
Haemostasis (ISTH) Virtual Congress, taking place on 12–14 July 2020.
The NuProtect study (NCT01712438) investigated the
immunogenicity, efficacy and safety of Nuwiq®
(simoctocog alfa) in 108 previously untreated patients with
haemophilia A. The final results of the study showed a
cumulative incidence of high-titre anti-FVIII inhibitors of
17.6%. Patients who completed the NuProtect study were
offered participation in a long-term extension study
(NCT01992549). The results of the extension study will be
presented for the first time at ISTH 2020.
In patients who develop inhibitors, immune tolerance
induction (ITI) with repeated FVIII administration is the
only proven approach to eradicate inhibitors. Three posters
will be presented at ISTH 2020 reporting on the success of
ITI with two of Octapharma’s FVIII products, octanate® and Nuwiq®.
The titles of the posters are provided below. All abstracts
are available on the ISTH website.
Poster PB0999 Long-term immunogenicity, efficacy and
safety of simoctocog alfa in patients with severe
haemophilia A who had completed the NuProtect PUP study
Poster PB1001 Immune tolerance induction (ITI) with a
single factor VIII/von Willebrand factor concentrate in
haemophilia A patients with inhibitors – Update from the ObsITI Study
Poster PB1044 Immune tolerance induction with octanate®
in patients with haemophilia A and inhibitors: An ongoing
case series from a Malaysian centre
Poster PB1047 Immune tolerance induction with
simoctocog alfa in patients with haemophilia A: An ongoing
multicentre case series from the UK
Octapharma will be sponsoring two scientific symposia at
ISTH 2020 on haemophilia A and von Willebrand disease
(VWD). The haemophilia A symposium will include new
clinical and real-world data on Nuwiq®, including final
results from the NuProtect study and its long-term
extension as well as experience with personalized
prophylaxis in previously treated patients. New studies of
ITI and the relevance of FVIII in managing joint and bone
health will also be discussed. The VWD symposium will
address the challenges of diagnosing VWD and particular
issues facing women with VWD, as well as discussing the
use of wilate® for prophylaxis and during surgery.
Both symposia will be held on Tuesday 14 July (8:45 am
EDT and 10:15 am EDT) on the ISTH virtual congress
platform and will be freely available to all healthcare
professionals. The symposia will remain on the congress
platform for 90 days and be available on the ISTH Academy
website for one year.
“We are very pleased to share the positive data across our
product portfolio addressing the needs of individuals with
haemophilia and von Willebrand disease”, said Dr Larisa
Belyanskaya, Head of IBU Haematology at Octapharma.
Olaf Walter, Board Member at Octapharma, added that “the
data cover the large spectrum of care required by patients
with coagulation disorders, and demonstrate Octapharma’s
commitment to improving patients’ lives at an individual
level.”
